Added value of amide proton transfer-weighted magnetic resonance imaging to Prostate Imaging Reporting and Data System version 2.1 in differentiating clinically significant prostate cancer

Amide proton transfer-weighted magnetic resonance imaging (APTw-MRI) and apparent diffusion coefficient (ADC) values can effectively differentiate clinically significant prostate cancer (csPCa). However, their added value in Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v. 2.1) rem...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Quantitative imaging in medicine and surgery Ročník 14; číslo 12; s. 9036
Hlavní autoři: Ye, Yinquan, Gong, Zijian, Song, Yiling, Yv, Lianyou, Liu, Zhixuan, Ying, Hongxing, Qiu, Jia, Dai, Jiankun, Peng, Yun, Gong, Lianggeng
Médium: Journal Article
Jazyk:angličtina
Vydáno: China 05.12.2024
Témata:
Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v. 2.1)
magnetic resonance imaging (MRI)
clinically significant prostate cancer (csPCa)
Amide proton transfer-weighted (APTw)
ISSN:2223-4292
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Abstract Amide proton transfer-weighted magnetic resonance imaging (APTw-MRI) and apparent diffusion coefficient (ADC) values can effectively differentiate clinically significant prostate cancer (csPCa). However, their added value in Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v. 2.1) remains uncertain. This study aimed to investigate the added value of APTw-MRI and ADC to PI-RADS v. 2.1 in differentiating csPCa. This study included 161 participants who underwent prostate biopsy or radical prostatectomy within 1 month following MRI. Six magnetic resonance (MR) parameters [minimum APT value (APTmin), maximum APT value (APTmax), mean APT value (APTmean), minimum ADC value (ADCmin), maximum ADC value (ADCmax), and mean ADC value (ADCmean)] and the PI-RADS score were acquired by two radiologists. Receiver operating characteristic (ROC) curve analysis was performed to evaluate and select parameters with the greatest performance from the APT and ADC values. Multivariate logistic regression analysis was conducted to construct models based on selected MR parameters and the PI-RADS score. The Delong test was applied to compare the area under the ROC curve (AUC) between models. The lesions of csPCa exhibited higher APT values and lower ADC values than not clinically significant prostate cancer (ncsPCa). The greatest comprehensive performance in differentiating csPCa was achieved by APTmean (AUC: 0.723; cutoff value: >1.644) and ADCmean (AUC: 0.759; cutoff value: <0.656). The addition of APTmean significantly improved the performance of the model based on the PI-RADS score (AUC: APT PI-RADS 0.867 PI-RADS 0.813; P=0.002). The introduction of ADCmean further improved the performance of the model based on APTmean and PI-RADS (AUC: combined model 0.875 PI-RADS 0.867, P=0.69), and it retained high diagnostic efficacy (AUC: 0.835) in the validation cohort. Further verification through calibration curve and decision curve analysis demonstrated that the adjusted PI-RADS model exhibited remarkable precision and practicality. APTw-MRI and ADC are valuable parameters for differentiating csPCa and can provide additional value for improving the efficiency and clinical benefit of PI-RADS v. 2.1.
AbstractList Amide proton transfer-weighted magnetic resonance imaging (APTw-MRI) and apparent diffusion coefficient (ADC) values can effectively differentiate clinically significant prostate cancer (csPCa). However, their added value in Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v. 2.1) remains uncertain. This study aimed to investigate the added value of APTw-MRI and ADC to PI-RADS v. 2.1 in differentiating csPCa.BackgroundAmide proton transfer-weighted magnetic resonance imaging (APTw-MRI) and apparent diffusion coefficient (ADC) values can effectively differentiate clinically significant prostate cancer (csPCa). However, their added value in Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v. 2.1) remains uncertain. This study aimed to investigate the added value of APTw-MRI and ADC to PI-RADS v. 2.1 in differentiating csPCa.This study included 161 participants who underwent prostate biopsy or radical prostatectomy within 1 month following MRI. Six magnetic resonance (MR) parameters [minimum APT value (APTmin), maximum APT value (APTmax), mean APT value (APTmean), minimum ADC value (ADCmin), maximum ADC value (ADCmax), and mean ADC value (ADCmean)] and the PI-RADS score were acquired by two radiologists. Receiver operating characteristic (ROC) curve analysis was performed to evaluate and select parameters with the greatest performance from the APT and ADC values. Multivariate logistic regression analysis was conducted to construct models based on selected MR parameters and the PI-RADS score. The Delong test was applied to compare the area under the ROC curve (AUC) between models.MethodsThis study included 161 participants who underwent prostate biopsy or radical prostatectomy within 1 month following MRI. Six magnetic resonance (MR) parameters [minimum APT value (APTmin), maximum APT value (APTmax), mean APT value (APTmean), minimum ADC value (ADCmin), maximum ADC value (ADCmax), and mean ADC value (ADCmean)] and the PI-RADS score were acquired by two radiologists. Receiver operating characteristic (ROC) curve analysis was performed to evaluate and select parameters with the greatest performance from the APT and ADC values. Multivariate logistic regression analysis was conducted to construct models based on selected MR parameters and the PI-RADS score. The Delong test was applied to compare the area under the ROC curve (AUC) between models.The lesions of csPCa exhibited higher APT values and lower ADC values than not clinically significant prostate cancer (ncsPCa). The greatest comprehensive performance in differentiating csPCa was achieved by APTmean (AUC: 0.723; cutoff value: >1.644) and ADCmean (AUC: 0.759; cutoff value: <0.656). The addition of APTmean significantly improved the performance of the model based on the PI-RADS score (AUC: APT PI-RADS 0.867 vs. PI-RADS 0.813; P=0.002). The introduction of ADCmean further improved the performance of the model based on APTmean and PI-RADS (AUC: combined model 0.875 vs. PI-RADS 0.867, P=0.69), and it retained high diagnostic efficacy (AUC: 0.835) in the validation cohort. Further verification through calibration curve and decision curve analysis demonstrated that the adjusted PI-RADS model exhibited remarkable precision and practicality.ResultsThe lesions of csPCa exhibited higher APT values and lower ADC values than not clinically significant prostate cancer (ncsPCa). The greatest comprehensive performance in differentiating csPCa was achieved by APTmean (AUC: 0.723; cutoff value: >1.644) and ADCmean (AUC: 0.759; cutoff value: <0.656). The addition of APTmean significantly improved the performance of the model based on the PI-RADS score (AUC: APT PI-RADS 0.867 vs. PI-RADS 0.813; P=0.002). The introduction of ADCmean further improved the performance of the model based on APTmean and PI-RADS (AUC: combined model 0.875 vs. PI-RADS 0.867, P=0.69), and it retained high diagnostic efficacy (AUC: 0.835) in the validation cohort. Further verification through calibration curve and decision curve analysis demonstrated that the adjusted PI-RADS model exhibited remarkable precision and practicality.APTw-MRI and ADC are valuable parameters for differentiating csPCa and can provide additional value for improving the efficiency and clinical benefit of PI-RADS v. 2.1.ConclusionsAPTw-MRI and ADC are valuable parameters for differentiating csPCa and can provide additional value for improving the efficiency and clinical benefit of PI-RADS v. 2.1.
Amide proton transfer-weighted magnetic resonance imaging (APTw-MRI) and apparent diffusion coefficient (ADC) values can effectively differentiate clinically significant prostate cancer (csPCa). However, their added value in Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v. 2.1) remains uncertain. This study aimed to investigate the added value of APTw-MRI and ADC to PI-RADS v. 2.1 in differentiating csPCa. This study included 161 participants who underwent prostate biopsy or radical prostatectomy within 1 month following MRI. Six magnetic resonance (MR) parameters [minimum APT value (APTmin), maximum APT value (APTmax), mean APT value (APTmean), minimum ADC value (ADCmin), maximum ADC value (ADCmax), and mean ADC value (ADCmean)] and the PI-RADS score were acquired by two radiologists. Receiver operating characteristic (ROC) curve analysis was performed to evaluate and select parameters with the greatest performance from the APT and ADC values. Multivariate logistic regression analysis was conducted to construct models based on selected MR parameters and the PI-RADS score. The Delong test was applied to compare the area under the ROC curve (AUC) between models. The lesions of csPCa exhibited higher APT values and lower ADC values than not clinically significant prostate cancer (ncsPCa). The greatest comprehensive performance in differentiating csPCa was achieved by APTmean (AUC: 0.723; cutoff value: >1.644) and ADCmean (AUC: 0.759; cutoff value: <0.656). The addition of APTmean significantly improved the performance of the model based on the PI-RADS score (AUC: APT PI-RADS 0.867 PI-RADS 0.813; P=0.002). The introduction of ADCmean further improved the performance of the model based on APTmean and PI-RADS (AUC: combined model 0.875 PI-RADS 0.867, P=0.69), and it retained high diagnostic efficacy (AUC: 0.835) in the validation cohort. Further verification through calibration curve and decision curve analysis demonstrated that the adjusted PI-RADS model exhibited remarkable precision and practicality. APTw-MRI and ADC are valuable parameters for differentiating csPCa and can provide additional value for improving the efficiency and clinical benefit of PI-RADS v. 2.1.
Author Ye, Yinquan
Song, Yiling
Qiu, Jia
Yv, Lianyou
Liu, Zhixuan
Peng, Yun
Ying, Hongxing
Dai, Jiankun
Gong, Zijian
Gong, Lianggeng
Author_xml – sequence: 1
  givenname: Yinquan
  surname: Ye
  fullname: Ye, Yinquan
  organization: Intelligent Medical Imaging of Jiangxi Key Laboratory, Nanchang, China
– sequence: 2
  givenname: Zijian
  surname: Gong
  fullname: Gong, Zijian
  organization: Intelligent Medical Imaging of Jiangxi Key Laboratory, Nanchang, China
– sequence: 3
  givenname: Yiling
  surname: Song
  fullname: Song, Yiling
  organization: Intelligent Medical Imaging of Jiangxi Key Laboratory, Nanchang, China
– sequence: 4
  givenname: Lianyou
  surname: Yv
  fullname: Yv, Lianyou
  organization: Department of Pathology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
– sequence: 5
  givenname: Zhixuan
  surname: Liu
  fullname: Liu, Zhixuan
  organization: Intelligent Medical Imaging of Jiangxi Key Laboratory, Nanchang, China
– sequence: 6
  givenname: Hongxing
  surname: Ying
  fullname: Ying, Hongxing
  organization: Intelligent Medical Imaging of Jiangxi Key Laboratory, Nanchang, China
– sequence: 7
  givenname: Jia
  surname: Qiu
  fullname: Qiu, Jia
  organization: Intelligent Medical Imaging of Jiangxi Key Laboratory, Nanchang, China
– sequence: 8
  givenname: Jiankun
  surname: Dai
  fullname: Dai, Jiankun
  organization: MRI research, GE Healthcare, Beijing, China
– sequence: 9
  givenname: Yun
  surname: Peng
  fullname: Peng, Yun
  organization: Intelligent Medical Imaging of Jiangxi Key Laboratory, Nanchang, China
– sequence: 10
  givenname: Lianggeng
  surname: Gong
  fullname: Gong, Lianggeng
  organization: Intelligent Medical Imaging of Jiangxi Key Laboratory, Nanchang, China
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39698702$$D View this record in MEDLINE/PubMed
BookMark eNo1kLlOAzEQQF0EcQRKWuSSZoOP3eymjLilSCCOOpq1x8Fo105sJyj_xsfhQJhmDj3NG80JGTjvkJBzzkaCM1lfrWwfC1EWnAs-IMdCCFmUYiKOyFmMnyxH3fCas0NyJCfjSVMzcUy-p1qjphvo1ki9odBbjXQZfPKOpgAuGgzFF9rFR8pcDwuHySoaMHoHTiG1eWbdgiZPn4OPCRLSx_3sBZc-pF0FTtMbSEBftzFhTzcYos0KMeLUOqqtyR50ycIvrjrrrIKu29JoF86a3Li0u-tPoHbqcEoODHQRz_Z5SN7vbt-uH4rZ0_3j9XRWKNk0qZjoRhlZ6RZb2Y5LEEwabiQopktmoKkrpscZqkteSWC8aVvDVS2NNoaj1mJILv_2Zv9qjTHNexsVdh049Os4l7ysuayqimX0Yo-u2x71fBnyf8J2_v9x8QPZoYjy
CitedBy_id crossref_primary_10_1007_s00261_025_04901_3
ContentType Journal Article
Copyright 2024 AME Publishing Company. All rights reserved.
Copyright_xml – notice: 2024 AME Publishing Company. All rights reserved.
DBID NPM
7X8
DOI 10.21037/qims-24-1121
DatabaseName PubMed
MEDLINE - Academic
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
ExternalDocumentID 39698702
Genre Journal Article
GroupedDBID 53G
AAKDD
ALMA_UNASSIGNED_HOLDINGS
DIK
HYE
NPM
OK1
RPM
7X8
ID FETCH-LOGICAL-c388t-9d8cf35dbeb3b64a203f1f3ac0d40fa8750d69d874153a018bbf1c73fdff1edd2
IEDL.DBID 7X8
ISICitedReferencesCount 1
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001390049200018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2223-4292
IngestDate Fri Sep 05 06:31:30 EDT 2025
Sun Mar 30 02:12:54 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords Prostate Imaging Reporting and Data System version 2.1 (PI-RADS v. 2.1)
magnetic resonance imaging (MRI)
clinically significant prostate cancer (csPCa)
Amide proton transfer-weighted (APTw)
Language English
License 2024 AME Publishing Company. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c388t-9d8cf35dbeb3b64a203f1f3ac0d40fa8750d69d874153a018bbf1c73fdff1edd2
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doi.org/10.21037/qims-24-1121
PMID 39698702
PQID 3147135550
PQPubID 23479
ParticipantIDs proquest_miscellaneous_3147135550
pubmed_primary_39698702
PublicationCentury 2000
PublicationDate 2024-12-05
PublicationDateYYYYMMDD 2024-12-05
PublicationDate_xml – month: 12
  year: 2024
  text: 2024-12-05
  day: 05
PublicationDecade 2020
PublicationPlace China
PublicationPlace_xml – name: China
PublicationTitle Quantitative imaging in medicine and surgery
PublicationTitleAlternate Quant Imaging Med Surg
PublicationYear 2024
SSID ssj0000781710
Score 2.2827847
Snippet Amide proton transfer-weighted magnetic resonance imaging (APTw-MRI) and apparent diffusion coefficient (ADC) values can effectively differentiate clinically...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 9036
Title Added value of amide proton transfer-weighted magnetic resonance imaging to Prostate Imaging Reporting and Data System version 2.1 in differentiating clinically significant prostate cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/39698702
https://www.proquest.com/docview/3147135550
Volume 14
WOSCitedRecordID wos001390049200018&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaAIsSFdx9Aq0HiavAriXNCVaFqD13tAaS9rRw_UKRu0u6GVvw3fhwzTrackJC4RFbkyJY8mfk8Hn8fY-_LWIXKeMObVBqO8brkdSGwFaVttEwpqJTFJqrZzC4W9XxKuG2mssqtT8yOOvSecuQftTSkJoeA-tPVNSfVKDpdnSQ07rMdjVCGSrqqhb3LsRCRTZUJCSgKclJmGmk2Veb1uW5XG64MR8gh_w4wc6A5ffq_U3zGnkwQE45Hm3jO7sXuBXt0MR2iv2S_jtHZBCCa7wh9ArdqQwQibOg7GDKQjWt-m3Om2G_lvnd00xFwY94TPUeEdpW1jWDoYU63RhCvwvn0bkT01HJdgM9ucDCyosPNmJoD9UFC28FWmmUg48Du2zualz-BikqohAlXneY1DuBp6PUr9u30y9eTMz6JOHCvrR14HaxPuggN7tqb0jgldJJJOy-CEcnhdkmEEjsRstFOoIU0SfpKp5CSjCGoXfag67u4z8DW3haNlUlUpfFFUzuLYSMlhKDeoGM6YO-267LEn4ROPlwX-x-b5Z-VOWB74-Iur0Y2j6Wuyxqdlnr9D1-_YY-VUJnoURRv2U5CFxEP2UN_M7Sb9VG2PnzO5he_Acks6as
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Added+value+of+amide+proton+transfer-weighted+magnetic+resonance+imaging+to+Prostate+Imaging+Reporting+and+Data+System+version+2.1+in+differentiating+clinically+significant+prostate+cancer&rft.jtitle=Quantitative+imaging+in+medicine+and+surgery&rft.au=Ye%2C+Yinquan&rft.au=Gong%2C+Zijian&rft.au=Song%2C+Yiling&rft.au=Yv%2C+Lianyou&rft.date=2024-12-05&rft.issn=2223-4292&rft.volume=14&rft.issue=12&rft.spage=9036&rft_id=info:doi/10.21037%2Fqims-24-1121&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2223-4292&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2223-4292&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2223-4292&client=summon